Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 10, 2007, Pages 1627-1634

  Tateishi, Ukihide ^a,b   Maeda, Tetsuo ^a   Morimoto, Tsuyoshi ^a   Miyake, Mototaka ^a   Arai, Yasuaki ^a   Kim, E Edmund ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; PET CT; Rectal; Stage

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; RECTUM CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CONTRAST MEDIA; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHIC IMAGE ENHANCEMENT; RECTAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34748837279     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0455-9     Document Type: Article

References (32)

1. Chiappa A, Biffi R, Bertani E, Zbar AP, Pace U, Crotti C, et al. Surgical outcomes after total mesorectal excision for rectal cancer. J Surg Oncol 2006;94:182-93.
2. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhart R, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989;170:329-32.
3. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22.
4. Ogunbiyi OA, Flanagan FL, Dehadashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-20.
5. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK Jr, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201.
6. Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17:894-901.
7. 18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-11.
8. 18F- fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 2000;180:1-5.
9. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2000;42:1s-93s.
10. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027-34.
11. 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med 2005;46:2020-8.
12. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005;104:2658-70.
13. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005;237:23-131.
14. Erturk SM, Ichikawa T, Fujii H, Yasuda S, Ros PR. PET imaging for evaluation of metastatic colorectal cancer of the liver. Eur J Radiol 2006;58:229-35.
15. Amthauer H, Denecke T, Rau B, Hildebrandt B, Hunerbein M, Ruf J, et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 2004;31:811-9.
16. 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003;44:1784-8.
17. 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut 2003;52 suppl:iv23-9.
18. Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004;232:815-22.
19. Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2006;33:779-84.
20. 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44:1797-803.
21. Delbeke D, Martin WH. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 2004;34:209-23.
22. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 2004;45 suppl:82S-95S.
23. Gearhart SL, Frassica D, Rosen R, Choti M, Schulick R, Wahl R. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 2006;13:397-404.
24. Veit P, Kuhle C, Beyer T, Kuehl H, Herborn CU, Borsch G, et al. Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut 2006;55:68-73.
25. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
26. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759-67.
27. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996;23:1409-15.
28. Miraldi F, Vesselle F, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 1998;23:3-7.
29. Leisure GP, Vesselle HJ, Faulhaber PF, O'Donnell JK, Adler LP, Miraldi F. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J Nucl Med Technol 1997;25:115-9.
30. Engel H, Steinert H, Buck A, Berthold T, Boni RAH, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996;37:441-6.
31. Cook GJR, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996;7:441-6.
32. Mawlawi O, Erasmus JJ, Munden RF, Pan T, Knight AE, Macapinlac HA, et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentogenol 2006;186:308-19.